Although luminal-like breast cancers are sensitive to ER-targeted therapy and HER2-positive breast cancers can benefit from Trastuzumab treatment3,4, TNBCs, whose first-line therapy is systematic conventional chemotherapy besides surgery or radiotherapy5, has no effective targeted therapy in the clinical setting. Here, ERBB2 is linked to breast cancer.